Chitosan-based nanoparticles as delivery-carrier for promising antimicrobial glycolipid biosurfactant to improve the eradication rate of Helicobacter pylori biofilm. Issue 6 (8th January 2021)

• Record Type: Journal Article
• Authors: Arif, Muhammad; Sharaf, Mohamed; Samreen, ; Khan, Sohaib; Chi, Zhe; Liu, Chen-Guang
• Is Part Of: Journal of biomaterials science. Volume 32:Issue 6(2021)
• Page Start: 813
• Page End: 832
• Publication Date: 2021-01-08
• Subjects: Chitosan -- rhamnolipids -- nanoparticles -- drug delivery systems -- antimicrobial; Polymers -- Biocompatibility -- Periodicals; Biomedical materials -- Periodicals; 572.33
• DOI: 10.1080/09205063.2020.1870323
• Languages: English
• ISSNs: 0920-5063

Abstract

Abstract: Driven by the need to find alternatives to control H. pylori infections, this work describes the development of chitosan-PMLA nanoparticulate systems as carriers for antimicrobial glycolipid. By using a simple ionic gelation method stable nanoparticle was obtained showing an encapsulation efficiency of 73.1 ± 1.3% and an average size of 217.0 ± 15.6 nm for rhamnolipids chitosan-PMLA nanoparticles (RL-CS-NPs). Glycolipid incorporation and particle size were correspondingly corroborated by FT-IR and TEM analysis. Rhamnolipids chitosan nanoparticles (RL-CS-NPs) presented the highest antimicrobial effect towards H. pylori (ATCC 26695) exhibiting a minimal inhibitory concentration of 132 µg/mL and a biofilm inhibition ability of 99%. Additionally, RL-CS-NPs did not interfere with human fibroblasts viability and proliferation under the tested conditions. The results revealed that the RL-CS-NPs were able to inhibit bacterial growth showing adequate cytocompatibility and might become, after additional studies, a valuable approach to fight H. pylori biofilm related-infections.